Hematologic Indices as Surrogate Markers for Monitoring Thiopurine Therapy in IBD

Digestive Diseases and Sciences

Volumn 60, Issue 2, 2015, Pages 478-484

  Kopylov, Uri ^a,b   Battat, Robert ^a,b   Benmassaoud, Amine ^a,b   Paradis Surprenant, Laurence ^a,b   Seidman, Ernest G ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

6 Thioguanine; Leukopenia; Macrocytosis; Thiopurines

Indexed keywords

6 METHYLMERCAPTOPURINE; 6 THIOGUANINE NUCLEOTIDE; HEMOGLOBIN; MERCAPTOPURINE; UNCLASSIFIED DRUG; 6-METHYLTHIOPURINE; 6-THIOGUANYLIC ACID; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; GUANINE NUCLEOTIDE; NUCLEOTIDE;

ACCURACY; ADULT; ARTICLE; CROSS-SECTIONAL STUDY; ERYTHROCYTE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; ANALOGS AND DERIVATIVES; BLOOD; BLOOD EXAMINATION; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG MONITORING; METABOLISM; PROCEDURES; THROMBOCYTE COUNT; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DRUG MONITORING; ERYTHROCYTE INDICES; FEMALE; GUANINE NUCLEOTIDES; HEMATOLOGIC TESTS; HEMOGLOBINS; HUMANS; LYMPHOCYTE COUNT; MALE; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 84922074520     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3362-5     Document Type: Article

References (21)

1. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis. 2010;4:28–62.
2. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohn’s Colitis. 2012;6:991–1030.
3. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743–1750.
4. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:15–36.
5. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731–743.
6. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16:1541–1549.
7. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3(Suppl 1):S30–S38.
8. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut. 1996;39:401–406.
9. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–713.
10. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987;41:18–25.
11. Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med. 2000;135:256–262.
12. D’Halluin PN, Tribut O, Branger B, et al. RBC 6-TGN and hematologic parameters in patients with Crohn’s disease treated by azathioprine. Gastroenterol Clin Biol. 2005;29:1264–1269.
13. Kim CJ, Park KI, Inoue H, et al. Azathioprine-induced megaloblastic anemia with pancytopenia 22 years after living-related renal transplantation. Int J Urol. 1998;5:100–102.
14. Soman S, Ashok D, Connolly SA, Cordell SJ, Taylor CJ, Campbell DI. Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine. Drugs R&D. 2010;10:213–217.
15. Thomas CW Jr, Lowry PW, Franklin CL, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflam Bowel Dis. 2003;9:237–245.
16. Glas J, Torok HP, Daczo J, Tonenchi L, Folwaczny M, Folwaczny C. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res. 2005;10:535–538.
17. Wickramasinghe SN, Dodsworth H, Rault RM, Hulme B. Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation. 1974;18:443–446.
18. Moreau AC, Paul S, Del Tedesco E, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflam Bowel Dis. 2014;20:464–471.
19. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904–915.
20. Lee LY, Santharam V, Macfaul G. Macrocytosis in Crohn’s disease: a devastating blast. BMJ Case Reports: 2013.
21. Robert Battat UK, Andrew Szilagyi, Anjali Saxena, David S. Rosenblatt, Margaret Warner, Talat Bessissow, Ernest Seidman, Alain Bitton Systematic review: vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation and management. Inflammatory Bowel Disease 2014 (in print).